Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.
Company profile
Website
CEO
Graham George Lumsden
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
26 Mar 20
6-K
Current report (foreign)
18 Mar 20
6-K
Current report (foreign)
5 Mar 20
6-K
Current report (foreign)
29 Jan 20
EFFECT
Notice of effectiveness
30 Dec 19
EFFECT
Notice of effectiveness
30 Dec 19
POS AM
Prospectus update (post-effective amendment)
23 Dec 19
POS AM
Prospectus update (post-effective amendment)
23 Dec 19
25
Voluntary exchange delisting
9 Dec 19
6-K
Current report (foreign)
27 Nov 19
Latest ownership filings
SC 13D/A
Motif Bio plc
28 Oct 19
SC 13D/A
Motif Bio plc
2 Apr 19
SC 13D/A
Motif Bio plc
15 Feb 19
SC 13G/A
Motif Bio plc
13 Feb 19
SC 13D
Motif Bio plc
11 Feb 19
SC 13G
Motif Bio plc
5 Feb 19
SC 13G
Motif Bio plc
14 Feb 18
SC 13D
Motif Bio plc
2 Feb 18
SC 13G/A
Motif Bio plc
8 Jan 18
SC 13G
Motif Bio plc
6 Sep 17
Institutional ownership, Q4 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|